Visionary ScienceDeveloping first-in-class therapeutics to protect the vision of patients with retinal disease.
ONL Therapeutics is pioneering an entirely new approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the Fas pathway.
OUR SCIENCE
ONL1204, the company’s lead therapeutic candidate is a first-in-class small peptide Fas inhibitor designed to protect the retina from cell death via both direct and inflammatory signaling in a range of retinal diseases.
OUR MILESTONES
Founded in 2011 and having raised more than $60 million to date, we’re methodically working our way towards our steadfast mission: to develop first-in-class therapeutics to protect the vision of patients with retinal disease.
OUR PARTNERSHIPS
As a company, we’re exploring, pushing boundaries, and revolutionizing. But, we couldn’t do any of what we do without the guidance and support of every one of our partners. They make what we do possible.